Diffuse Alveolar Hemorrhage (DAH) - PowerPoint PPT Presentation

About This Presentation
Title:

Diffuse Alveolar Hemorrhage (DAH)

Description:

Diffuse Alveolar Hemorrhage (DAH) Internal Medicine Lecture Howard M. Mintz, M.D. October 14, 2004 Etiologies of DAH Many causes and clinical syndromes Pathology of ... – PowerPoint PPT presentation

Number of Views:286
Avg rating:3.0/5.0
Slides: 88
Provided by: HowardM151
Category:

less

Transcript and Presenter's Notes

Title: Diffuse Alveolar Hemorrhage (DAH)


1
Diffuse Alveolar Hemorrhage (DAH)
  • Internal Medicine Lecture
  • Howard M. Mintz, M.D.
  • October 14, 2004

2
(No Transcript)
3
Hallmarks of DAH
  • Hemoptysis (may be absent in 1/3 of cases)
  • Diffuse pulmonary infiltrates
  • Anemia
  • Hypoxemic respiratory failure

4
Etiologies of DAH
  • Many causes and clinical syndromes

5
(No Transcript)
6
Pathology of DAH
  • 3 Broad histologic patterns identified
  • Pulmonary capillaritis
  • Bland pulmonary hemorrhage
  • Diffuse alveolar damage

7
Pulmonary Capillaritis I
  • Most common of the histologic patterns
  • First described by Spencer in 1957
  • Neutrophilic interstitial infiltrate with
    fragmentation of neutrophils (leukocytoclasis)
    and pyknotic neutrophils with release of
    cytokines
  • Nuclear dust in interstitium and alveolar spaces

8
Pulmonary Capillaritis II
  • Disruption of the interstitium and capillaries
    with leakage of blood and fibrin into alveolar
    spaces
  • Edema of basement membrane with subsequent
    necrosis of interstitium and eventual fibrosis
  • Neutrophils are seen lining the interstitium

9
(No Transcript)
10
(No Transcript)
11
Diffuse Alveolar Damage
  • Hyaline membrane formation, alveolar and
    interstitial edema, microthrombi, and capillary
    congestion are present
  • See slide

12
(No Transcript)
13
Bland Alveolar Hemorrhage
  • RBCs in the alveolar spaces, but alveolar walls
    appear normal except for type II epithelial cell
    hyperplasia
  • See slide

14
(No Transcript)
15
(No Transcript)
16
Clinical Presentation of DAH I
  • Patients often have an underlying known condition
  • Hemoptysis can be acute or subacute, but
    typically presents within one week of onset
  • Majority of patients are less than forty years
    old
  • 1/3 do not have hemoptysis, but present with
    dyspnea and cough

17
Clinical Presentation DAH II
  • In patients without hemoptysis, diagnosis is
    confirmed by the presence of blood on serial BAL
  • Anemia
  • Pulmonary infiltrates
  • Chest pain, nonspecific
  • Symptoms of underlying disease processes

18
History in DAH
  • Careful drug history
  • Smoking history
  • History of underlying illnesses such as valvular
    heart disease, cytotoxic agents, drugs
  • Social history, in particular cocaine usage
  • History of any renal, skin, or eye diseases

19
Physical Findings in DAH
  • Nonspecific
  • Fevers, rales, signs of consolidation
  • Synovitis, iridocyclitis, myositis, palpable
    purpura

20
(No Transcript)
21
Radiographic Findings in DAH
  • Nonspecific, focal or generalized infiltrates
  • Rapidly progressive bilateral infiltrates
  • Interstitial fibrosis in presence of recurrent
    disease
  • Kerleys B line suggestive of valvular etiology,
    also in conditions associated with myocarditis,
    venoocclusive disease

22
(No Transcript)
23
(No Transcript)
24
(No Transcript)
25
Laboratory Findings in DAH I
  • Low or falling hematocrit or hemoglobin
  • In the setting of chronic or recurrent episodes,
    low serum iron
  • Nonspecific elevations of white count
  • Thrombocytopenia
  • Elevation of ESR
  • Proteinuria, microscopic hematuria, casts suggest
    glomerulonephrits

26
Laboratory Findings in DAH II
  • Hypoxemia
  • Elevation of DLCO
  • Restrictive pattern associated with fibrosis or
    obstructive patterns with marked emphysematous
    changes
  • ANCA
  • ABMA, IgG

27
ANCA in DAH Diagnosis
  • Antineutrophilic cytoplasmic antibodies
    (ANCA)first described in 1982 in association with
    pauci-immune glomerulonephritis
  • ANCA described in association with Wegeners
    granulomatosis in 1985
  • Subsequently described in microscopic polyangitis
    (MPA) and limited renal vasculitis

28
(No Transcript)
29
ANCA Testing
  • Indirect immunofluorescence assay (IIA) is more
    sensitive
  • Enzyme link immunosorbent assay (ELISA) is more
    specific
  • Best used in conjunction with IIA for screening
    and ELISA for confirmation
  • Two relative antigens in vasculitic diseases,
    proteinase 3 (PR3) and myeloperoxidase (MPO)
  • Antigens are found in neutrophils and monocytes
  • PR3-ANCA and MPO-ANCA

30
Immunofluorescence Patterns In Vasculitis
  • Sera from patients with suspected ANCA related
    vasculitis are incubated in ethanol fixed
    neutrophils
  • Two distinct patterns of fixation identified,
    c-ANCA with cytoplasmic pattern and p-ANCA with
    perinuclear pattern
  • c-ANCA pattern is typically associated with
    antibodies against PR3
  • p-ANCA is typically associated with antibodies
    against MPO
  • See photographics

31
(No Transcript)
32
(No Transcript)
33
Immunofluorescence Utility and Errors
  • Tests are visually graded and inspected
  • Tests are not specific and false positives and
    negatives can occur
  • IIA testing should be confirmed with ELISA
    testing for PR3 and MPO

34
(No Transcript)
35
Specific Examples of DAH
  • Capillaritis-Microscopic Polyangiitis
  • Diffuse Alveolar Damage-Crack Cocaine
  • Bland Hemorrhage-Amiodarone

36
Microscopic Polyangiitis (MPA) I
  • Rare disease with prevalence estimated 3 cases
    per million
  • Etiology is unknown
  • Small vessel involvement including arterioles,
    venules, and or capillaries
  • Immune complexes are not demonstrated
  • Typical presentation is that of renal failure
    with glomerulonephritis and hemoptysis with
    capillaritis
  • Histopathologically segmental distribution,
    neutrophilic infiltration, and fibrinoid necrosis
    (See slide)

37
MPA II
  • ANCA is positive in about 75 of patients
  • p-ANCA is present with MPO by ELISA in 85 of
    patients
  • c-ANCA is rare with PR3 by ELISA
  • Systemic disease
  • Skin manifestations including splinter
    hemorrhages and purpura
  • Musculoskeletal with arthralgias, myalgias,
    arthritis
  • Gastrointestinal with abdominal pain and GI
    hemorrhage
  • Neurological with peripheral neuropathy

38
MPA II
  • ANCA is positive in about 75 of patients
  • p-ANCA is present with MPO by ELISA in 85 of
    patients
  • c-ANCA is rare with PR3 by ELISA
  • Systemic disease
  • Skin manifestations including splinter
    hemorrhages and purpura
  • Musculoskeletal with arthralgias, myalgias,
    arthritis
  • Gastrointestinal with abdominal pain and GI
    hemorrhage
  • Neurological with peripheral neuropathy

39
MPA III
  • Prominent gastrointestinal signs and symptoms and
    lack of upper airway disease helps distinguish
    from Wegeners
  • Classical polyarteritis nodosa rarely involves
    the lung
  • 45 of patients have circulating immune complexes
    but tissue localization is rare, pauci-immune
    disease
  • 33 of patients have antibodies to hepatitis C or
    B
  • Treatment same as for Wegeners
  • Survival about 65 with recurrence associated
    with tapering of therapy
  • Case report in which MPA eventually developed
    features of WG

40
The histologic section from a right middle lobe
open lung biopsy showed extensive hemorrhaging in
the alveolar spaces
Maimon, N. et al. Chest 20031242384-2387
41
Pulmonary Interstitial Fibrosis MPA
  • Report of six cases of PIF in which patients were
    ANCA positive and eventually diagnosed with MPA
  • The diagnosis of PIF may precede that of MPA by
    many years
  • See CT

42
(No Transcript)
43
Diffuse alveolar consolidation with air
bronchogram involving the entire right lung field
Maimon, N. et al. Chest 20031242384-2387
44
(No Transcript)
45
Cocaine History Mechanisms of Action
  • First isolated from coca leaves in 1859
  • Part of the original formulation of Coke, removed
    in 1906
  • First reported deaths occurred in 1893
  • Potent sympathomimetic and CNS stimulant based on
    its ability to block reuptake of catecholamines
    serotonin
  • Cocaine HCL boiled with baking soda and extracted
    with ether or alcohol, yields heat stable Crack
    or Rock
  • Smoked and reaches the CNS within seconds with
    half life of 60-90 minutes
  • Frequently mixed with marijuana or tobacco

46
Crack Cocaine with Diffuse Alveolar Damage
  • Cocaine is abused in two forms, cocaine HCl and
    cocaine alkaloidal
  • The alkaloidal form or crack cocaine is lipid
    soluble and resistant to thermal breakdown
  • Rapidly absorbed from the lung via pulmonary
    capillary network
  • Euphoria is similar to that of intravenous usage
  • Smoking of crack is also associated with
    absorption of impurities, ignition products and
    thermal breakdown products of cocaine

47
BAL in Crack Lung Users
  • Up to 40 of of crack cocaine users have
    hemosiderin stained alveolar macrophages. lt1 of
    nonsmokers at autopsy have this finding. 9 of
    smokers have this finding.
  • Endothelin (ET)-1, an endothelium-derived
    vasoconstrictor peptide, indicator of cell damage
    is also found in a higher proportion of crack
    cocaine users. ET-1 is found in a high proportion
    of BAL samples from crack users and is felt to
    be a marker of alveolar capillary damage
  • BAL in crack cocaine users have an absolute
    increase in hemosiderin stained alveolar
    macrophages

48
Iron content of alveolar macrophages (AM)
Janjua, T. M. et al. Chest 2001119422-427
49
Ferritin content of alveolar macrophages recovered
Janjua, T. M. et al. Chest 2001119422-427
50
Prominent hemosiderin-laden AMs in the BAL fluid
of a CS (left, A), which are absent in the BAL
fluid of a TS (middle, B) or a NS (right, C)
Baldwin, G. C. et al. Chest 20021211231-1238
51
Increased percentage of hemosiderin-positive AMs
in the BAL specimen of cocaine smokers
Baldwin, G. C. et al. Chest 20021211231-1238
52
Acute Lung Injury with Crack
  • Typically develops within 1-48 hours
  • 25 of users with develop respiratory symptoms
    including fever, cough, nonspecific chest pain,
    hemoptysis, back pain, hyperpnea, dyspnea,
    melanoptysis, wheezing
  • Diffuse pulmonary infiltrates, eosinophilic
    pleural effusions, acute lung injury pattern
  • Eosinophilia

53
Crack Pulmonary Injuries I
  • Barotrauma, ischemia, provocation of inflammatory
    damage, and direct cellular toxicity
  • Barotrauma is the result of Valsalva maneuver
    after inhalation and the forceful inhalation of
    air into partners. Pneumothoraces,
    pneumomediastinum, and pneumopericardium
  • Ischemia is the result of the vasoconstrictive
    properties
  • Severe bronchospasm in patients with preexisting
    asthma

54
Crack Cocaine Pulmonary Injuries II
  • Case of bilateral infiltrates and bilateral hilar
    adenopathy mimicking sarcoid, probably induced by
    contaminants in crack
  • The morphologic features of squamous metaplasia
    and mucus gland hypertrophy similar to that of
    cigarette smokers, possibly increased risk of
    lung cancer

55
Microenvironment and Cocaine
  • Cocaine inhibits alveolar macrophages ability to
    kill most bacteria and tumor cells in vitro
  • Cocaine users are unable to kill bacteria using
    nitric oxide as an antibacterial effector
    molecule
  • These changes may predispose to increase
    pulmonary infections in these users.
  • Marijuana has similar adverse effects. Inhibits
    phagocytosis Staph aureus
  • Both drugs frequent smoked together

56
Distribution of Vc and DMCO in the
cross-sectional cohort is shown
Kleerup, E. C. et al. Chest 2002122629-638
57
Chronic Exposure to Crack
  • Pulmonary fibrosis
  • Diffuse alveolar hemorrhage
  • Hemosiderosis
  • Pulmonary infarction
  • Eosinophilic interstitial lung disease
  • Bullous emphysema
  • Medial artery hypertrophy
  • Noncardiogenic pulmonary edema
  • Increased risk of pneumonia, multifactorial
    problem

58
Treatment of Crack Lung
  • Need to make history of exposure
  • Supportive
  • Role of steroids unproven, helpful in those
    patients with bronchospasm
  • Screen for HIV and concomitant drugs
  • Drug treatment

59
Amiodarone Lung Disease
  • Drugs characteristics
  • Expanding scope of the problem
  • Clinical presentations
  • Radiographic presentations
  • Diagnosis and therapeutic options

60
Trends in receipt of clinically serious, domestic
spontaneous adverse event reports (1,941) in
association with amiodarone (all forms) with
further indication of the subset of reports coded
for parenchymal lung injury (n 280)
Brinker, A. et al. Chest 20041251591-a-1592-a
61
Incidence of atrial fibrillation in the therapy
group vs the control group
Kerstein, J. et al. Chest 2004126716-724
62
Comparison of length of stay (los) in the
amiodarone group and the control group
Kerstein, J. et al. Chest 2004126716-724
63
PHD Amiodarone Usage 1997-2003
64
Characteristics of Amiodarone I
  • Principal metabolite is desethyl-aminodarone or
    DEAm
  • DEAm and amiodarone are toxic to lung tissue
  • Propensity for accumulation in lung tissue with a
    ratio of plasma to lung of 1500
  • DEAm and amiodarone also have a propensity to
    accumulate in the liver and skin
  • Amiodarone and DEAm are localized in lysosomes
    and block the removal of phospholipids

65
Characteristics of Amiodarone II
  • Amiodarone drug levels do not predict the
    development of pulmonary toxicity
  • DEAm levels are higher in patients who develop
    amiodarone pneumonitis that controls
  • The foamy macrophage on BAL is characteristic of
    amiodarone exposure and its absence bespeaks
    against this diagnosis
  • Clearance of amiodarone is very slow with
    biopsies demonstrating the drug after one year of
    cessation of therapy

66
Characteristics of Amiodarone III
  • Clinically the development of amiodarone
    infiltrates is associated with a prolonged
    radiographic resolution because of the prolonged
    deposition of this agent
  • Each molecule of amiodarone and DEAm contain two
    iodines
  • The presence of the iodines explains the frequent
    development of thyroid dysfunction in patients
    receiving amiodarone
  • The iodine also explains the increase in CT
    density in liver and lung in patients diagnosed
    with pulmonary toxicity

67
(No Transcript)
68
(No Transcript)
69
(No Transcript)
70
Amiodarone Pulmonary Toxicity
  • First clinical description in 1980, although drug
    was introduced in 1969 in Europe
  • Rat models have demonstrated the toxicity since
    1987
  • The histological features of amiodarone toxicity
    are relatively distinctive in nature, foamy
    macrophages
  • There is a relative dose relationship between
    total cumulative dose and incidence of toxicity
  • Reintroduction of agent to patient with previous
    toxicity results in recurrence of syndrome

71
Relationship Between Dose and Incidence of
Toxicity to Amiodarone
  • Estimated that 50 of patients receiving 1200 mg
    per day will develop toxicity
  • Estimated incidence 5 to 15 if dose is greater
    than or equal to 500 mg per day
  • Estimated incidence 0.1 to 0.5 in dose is less
    than 200 mg per day
  • Overall incidence is probably in the range of 4
    to 6

72
Onset of Toxicity to Amiodarone
  • Majority of cases will occur within one year of
    exposure
  • May occur following loading intravenous dose
  • Cases described after 10 years of therapy
  • Can develop following cessation of therapy
  • Toxicity increases in certain patient populations
    including advanced age, cardiac surgery,
    pulmonary surgery, ARDS, insertion of ICD
  • Common denominator is exposure to high FIO2
    during surgery, similar to situation in bleomycin
    pulmonary toxicity and radiation

73
Radiographic Presentations in Amiodarone
Pulmonary Toxicity
  • Subacute pneumonitis
  • Single of multiple subpleural masses
  • Pulmonary fibrosis
  • Organizing pneumonia
  • ARDS
  • Alveolar hemorrhage

74
Subacute Amiodarone Pneumonitis
  • Patchy or diffuse infiltrates
  • Suggestion of RUL predominance on plain
    radiographic examination, usually not confirmed
    by HRCT, bilateral process
  • Alveolar interstitial pattern on HRCT
  • Increased attenuation on HRCT
  • Pleural effusion rare

75
Subpleural Masses in Amiodarone Lung Disease
  • Single or multiple
  • Typically abut the pleura
  • Chest pain and pleural rub
  • DDX includes pulmonary infarction, malignancy,
    pneumonia, lymphoma

76
(No Transcript)
77
Pulmonary Fibrosis with Amiodarone
  • Very uncommon, lt0.1 of cases
  • Setting of prior acute pneumonitis from
    amiodarone or resolving phase of illness or as
    initial presentation
  • Differs from idiopathic pulmonary fibrosis by the
    rapidity of disease progression and history of
    amiodarone usage
  • Reticular infiltrates at the bases with typical
    signs symptoms of ILD
  • Irreversible
  • Not felt to be steroids responsive

78
Organizing Pneumonia from Amiodarone
  • Indistinguishable from other forms of organizing
    pneumonia
  • Migratory infiltrates may occur
  • See radiographs

79
(No Transcript)
80
ARDS from Amiodarone
  • Settings cardiac surgery, pulmonary resection,
    and following defibrillator implantation (J.
    Intern Medicine Med 2001, Liverani up to 10
    incidence) lung biopsy for diagnosis
  • 50 fatality
  • Rapidly progressive pulmonary infiltrates with
    hypoxemic respiratory failure
  • Poorly responsive to therapy

81
Subclinical Disease from Amiodarone
  • Setting of chronic therapy
  • Plain radiographs typically normal
  • HRCT ground glass infiltrates
  • Typically responds to cessation of drug
  • Unclear if it is progressive
  • Biopsy foamy cells and inflammatory cells evident
  • Gallium scans positive, but T99 more sensitive

82
Diagnosis and Management I
  • Clinical lab increase in LDH sensitive, but not
    specific, increased ESR, and some leukocytosis
  • PFTs most sensitive with reduction in DLCO as
    first abnormality.
  • A fall in DLCO does not necessarily indicate
    pulmonary toxicity, only 1/3 of patients develop
    overt disease
  • A fall of 15 is cutoff for sensitivity and 30
    for specificity according to Mayo study

83
Diagnosis and Management II
  • Stable DLCO is indicative of absence of toxicity,
    but fall should be confirmed with HRCT/nuclear
  • No clear cut benefit to routine screening, but
    study for Canada suggests baseline chest x-ray
    and PFTs, serial studies in patients with new
    symptoms
  • BAL is nonspecific, finding of foamy macrophages
    is not indicative of toxicity, only exposure
  • HRCT and nuclear imaging important in
    confirmation of diagnosis
  • KL6, high molecular weight, glycoprotein, type II
    pneumocytes, increased

84
Diagnosis and Management III
  • Cessation of drug is mainstay of therapy
  • Steroids help in certain cases, but not uniformly
  • Steroids must be tapered very slowly and over a
    prolonged period of time. Early mortality is
    increased in patients not started on steroids.
  • Radiographic and PFT improvement follow clinical
    improvement
  • Permanent reduction in DLCO is possible.
  • Recurrent disease with cessation of steroids is
    frequently resistant to therapy

85
Diagnosis and Management IV
  • Steroids 0.75 mg/kg to 1.0 mg/kg or
    methylprednisolone or equivalent.
  • Treat at least for six months, preferably for one
    year
  • No reduction in dosage until objective evidence
    of improvement
  • Incidence is higher in patients with COPD as is
    mortality
  • Mortality up to 33
  • 2/3 of patients will develop recurrent disease if
    reexposed to the medication, DO NOT RECHALLENGE!!

86
Diagnosis and Management V
  • Clinical clues to suggest condition would include
    concomitant skin discoloration, thyroid
    dysfunction, myeloid suppression,
    photosensitivity, corneal deposits with chronic
    therapy

87
Potential Mechanism of Toxicity for Amiodarone
  • Hamster alveolar macrophages are sensitive to
    amiodarone
  • When amiodarone is added to preparation of
    hamster alveolar macrophages, the membrane
    potential declines
  • Following the decline in the membrane potential,
    decline in intracellular ATP
  • Decline in cell viability identified
Write a Comment
User Comments (0)
About PowerShow.com